window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

About Novigenix

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.

Interview Jan Groen: Colorectal Cancer Blood Test Driven by Immuno-transcriptomics

By |2019-06-19T15:11:14+02:0019 June 2019|News Novigenix|

Source: TNMichele Wilson PhDScience Writer Immuno-transcriptomics is a field of study focused on analyzing gene expression modifications (mRNA signatures) induced by the immune response to various triggers, such as the onset of cancer. Through deep neural network and machine learning, Novigenix are generating mathematical models based on these mRNA signature analyses to predict the onset and progression

Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director

By |2019-08-23T17:21:16+02:0018 June 2019|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational

Novigenix Developing NGS Version of Early Colorectal Cancer Detection Test

By |2019-08-23T17:23:56+02:0017 May 2019|Medical information, News Novigenix|

NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR. The firm began a study earlier this year to validate the assay, which measures cancer-specific transcriptomic

Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company

By |2019-05-13T13:36:00+02:0013 May 2019|Communiqué de presse, News Novigenix|

ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection   LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief

Colorectal cancer screening should be self-evident

By |2018-04-19T10:03:59+02:005 April 2018|Screening|

PREVENTION : Colorectal cancer screening is voluntary but the physicians strongly recommend it   Prof. Dr. med. Christoph Beglinger  - Specialist of Gastroenterology   Colorectal Cancer - Screening : Now, there are three options for the prevention.   Switzerland lags behind regarding colorectal cancer screening, according to international comparison. Only 30% of men and women over the age of

Load More Posts